Dr. Jonathan McConathy, MD, PhD
Claim this profileUniversity of Alabama at Birmingham Medical Center
Studies Neuroinflammatory Disease
Studies Healthy Subjects
18 reported clinical trials
17 drugs studied
Area of expertise
1Neuroinflammatory Disease
rs6971 positive
Stage III
rs6971 negative
2Healthy Subjects
Affiliated Hospitals
Clinical Trials Jonathan McConathy, MD, PhD is currently running
PET Scan with DPA-714
for Parkinson's Disease
The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \[18F\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \[18F\]DPA-714-PET/MRI.
Recruiting1 award Phase 1 & 2
PET/MRI Brain Imaging
for Alzheimer's Disease
This trial uses a special imaging dye to detect harmful protein build-up in the brains of participants from the UAB Alzheimer's Disease Center. The study aims to understand how these brain changes relate to race, vascular risk factors, and cognitive health. The dye helps make these harmful proteins visible in brain scans.
Recruiting1 award Phase 2
More about Jonathan McConathy, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 18 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Jonathan McConathy, MD, PhD has experience with
- [18F]DPA-714
- [11C]PiB
- 18F-labeled DPA-714
- [18F]FMISO
- DPA-714
- [F-18]DPA714
Breakdown of trials Jonathan McConathy, MD, PhD has run
Neuroinflammatory Disease
Healthy Subjects
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan McConathy, MD, PhD specialize in?
Jonathan McConathy, MD, PhD focuses on Neuroinflammatory Disease and Healthy Subjects. In particular, much of their work with Neuroinflammatory Disease has involved rs6971 positive patients, or patients who are Stage III.
Is Jonathan McConathy, MD, PhD currently recruiting for clinical trials?
Yes, Jonathan McConathy, MD, PhD is currently recruiting for 10 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Jonathan McConathy, MD, PhD has studied deeply?
Yes, Jonathan McConathy, MD, PhD has studied treatments such as [18F]DPA-714, [11C]PiB, 18F-labeled DPA-714.
What is the best way to schedule an appointment with Jonathan McConathy, MD, PhD?
Apply for one of the trials that Jonathan McConathy, MD, PhD is conducting.
What is the office address of Jonathan McConathy, MD, PhD?
The office of Jonathan McConathy, MD, PhD is located at: University of Alabama at Birmingham Medical Center, Birmingham, Alabama 35249 United States. This is the address for their practice at the University of Alabama at Birmingham Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.